Founded by NIH and Johns Hopkins genomics researchers, and an entrepreneur with 2 successful exits, Predictiv is a DNA-based digital twin to predict and prevent over 16,000 diseases, and simulate personalized adverse reactions to more than 300 drugs. Thanks to its patented AI and bioinformatics technology, Predictiv is today by far the most complete solution on the market.
We have launched our beta version and plan to deploy the solution in November. We have today 8 physicians who will use it during the pilot period and have had advanced discussions with several renowned hospitals, biobanks and large Telemedicine companies.
We target in priority healthcare professionals (concierge medicine doctors, hospitals, telemedicine companies, health insurance companies) to provide our solution to the 67% of US adults interested in getting genetic testing to determine if they are at risk for any diseases or conditions (source: Statista)
Problem or Opportunity
Over 10% of serious diseases have a genetic component that could have been prevented: - 12% of adult hospital admissions are for genetic causes - 15% of all cancers have an inherited susceptibility - 10% of chronic diseases (diabetes, heart disease, Alzheimer) have a significant genetic component.
Solution (product or service)
By enabling the physicians to identify genetic predispositions and their impact upon the patients, we can significantly decreases the number of diseases. That means a better quality of life for patients, a more accurate service for physicians and reduced costs for insurance companies.
Today, most existing alternatives have either a limited scope (23andMe, Invitae...) or include a fully manual analysis (genetic counselors...).
Advantages or differentiators
Predictiv has the most complete coverage: - 99% genes vs <1% for existing alternatives - 16,000 diseases vs <200 for existing alternatives
Thanks to its Bioinformatics pipeline and AI engine, Predictiv is also the only solution of the market that has been able to automate more than 95% of the whole genome analysis process.
Based on a standard price of $490 per Digital Twin (genomics database and analysis), we forecast revenues over $75M by 2024. The operating margin is over 75% as most of our costs will be on R&D and Growth.
Predictiv sells its solution through healthcare professionals (mainly physicians). The patient pays for it and get (partly or in full) reimbursed by his insurance company.
Money will be spent on
- $250k for the R&D to further improve our solution and keep the technology lead - $150k on sales and business development to finalize the ongoing discussions on partnerships - $100k on IT and operations to run the company and provide the required support to our clients
Offer for investor
We plan to raise SAFE on a $5M max cap. We are nevertheless open to other instruments (convertible notes...)
Predictive medicine is a relatively new market and some education might have to be done towards healthcare professionals to explain them the benefits for them and their patients. Nevertheless, considering the cost and scope of Predictiv, we are extremely confident they will use a full solution for a lower cost than most existing alternatives.
Incubation/Acceleration programs accomplishment
Plug and Play Techcenter (Sunnyvale, CA), ongoing
Won the competition and other awards
Startup of the Year Top 100
- Bioinformatics Pipeline: 506095170 - Deep Learning Incorporated Systems and methods of Multi-dimensional Polygenic Score for One’s Disease Risk Prediction: 63086042